Literature DB >> 6341070

Carbamazepine versus diphenylhydantoin in the treatment of myotonia.

G P Sechi, S Traccis, L Durelli, F Monaco, R Mutani.   

Abstract

A double-blind controlled trial was performed on 6 patients affected with Steinert's disease in order to evaluate the efficacy of two different dosages of diphenylhydantoin (PHT, 200 and 300 mg/day) and carbamazepine (CBZ, 600 and 800 mg/day) on the myotonic afterdischarge. Both dosages of PHT and CBZ induced a significant improvement of myotonia. For PHT a trend towards decreased efficacy is pointed out at toxic or at high dosages.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6341070     DOI： 10.1159/000115546

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


  9 in total

1.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

2.  Efficacy of carbamazepine on cerebellar tremors in patients with superior cerebellar artery syndrome.

Authors:  G P Sechi; A Pirisi; V Agnetti; M Piredda; M Zuddas; S Tanca; M L Piras; I Aiello; F Deserra; G Rosati
Journal:  J Neurol       Date:  1989-12       Impact factor: 4.849

3.  Myotonia congenita and myotonic dystrophy: surveillance and management.

Authors:  Allison Conravey; Lenay Santana-Gould
Journal:  Curr Treat Options Neurol       Date:  2010-01       Impact factor: 3.598

4.  Myotonia congenita--a successful response to carbamazepine.

Authors:  M R Savitha; B Krishnamurthy; Abbas Hyderi; Nallur B Ramachandra
Journal:  Indian J Pediatr       Date:  2006-05       Impact factor: 1.967

Review 5.  Treatment Updates for Neuromuscular Channelopathies.

Authors:  Nantaporn Jitpimolmard; Emma Matthews; Doreen Fialho
Journal:  Curr Treat Options Neurol       Date:  2020-08-22       Impact factor: 3.598

Review 6.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

8.  Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.

Authors:  Jean-François Desaphy; Roberta Carbonara; Teresa Costanza; Diana Conte Camerino
Journal:  Exp Neurol       Date:  2014-03-05       Impact factor: 5.330

9.  Dystrophia myotonica type 1 presenting with dysarthria: A case report and literature review.

Authors:  Chunrong Li; Xiaoling Zhang; Chunkui Zhou; Lijun Zhu; Kangding Liu; Shaokuan Fang
Journal:  Exp Ther Med       Date:  2017-06-12       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.